Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction

British Journal of Clinical Pharmacology

Volumn 77, Issue 2, 2014, Pages 337-356

  Pérez De Los Cobos, José ^a   Siñol, Núria ^a   Pérez, Víctor ^a,b   Trujols, Joan ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

addiction; adult attention deficit hyperactivity disorder; atomoxetine; clinical practice; stimulants; substance use disorders

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; BROMOCRIPTINE; DEXAMPHETAMINE; FLUOXETINE; LISDEXAMFETAMINE; METHAMPHETAMINE; METHYLPHENIDATE; NICOTINE PATCH; PEMOLINE; VENLAFAXINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; AGITATION; ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOLISM; ANXIETY; APPLICATION SITE REACTION; ARTICLE; ATTENTION DEFICIT DISORDER; BLURRED VISION; CANNABIS ADDICTION; CHEST TIGHTNESS; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; COMORBIDITY; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; INSOMNIA; LOCAL SKIN REACTION; MENTAL DISEASE; NAUSEA; NERVOUSNESS; PANIC; PARESTHESIA; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; PSYCHOTHERAPY; RASH; RELAPSE; SKIN TINGLING; SLEEP DISORDER; SUBSTANCE ABUSE; THORAX PAIN; TOBACCO DEPENDENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ADDICTION; ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; ATOMOXETINE; CLINICAL PRACTICE; STIMULANTS; SUBSTANCE USE DISORDERS;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COMBINED MODALITY THERAPY; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; METHYLPHENIDATE; PHYSICIAN'S PRACTICE PATTERNS; PROPYLAMINES; PSYCHOTHERAPY; SUBSTANCE-RELATED DISORDERS;

EID: 84893069360     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12045     Document Type: Article

References (97)

1. van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F, Crunelle CL, Swets M, Schoevers RA,. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend 2012; 122: 11-19.
2. Newcorn JH,. Co-morbidity in adults with ADHD. CNS Spectr 2008; 13 (8 Suppl. 12): 12-15.
3. Urcelay GP, Dalley JW,. Linking ADHD, impulsivity, and drug abuse: a neuropsychological perspective. Curr Top Behav Neurosci 2012; 9: 173-197.
4. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P,. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry 2010; 10: 67. doi: 10.1186/1471-244X-10-67.
5. Greenfield B, Hechman L,. Treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 2005; 5: 107-121.
6. Wilens TE, Morrison NR, Prince J,. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother 2011; 11: 1443-1465.
7. Fatseas M, Debrabant R, Auriacombe M,. The diagnostic accuracy of attention-deficit/hyperactivity disorder in adults with substance use disorders. Curr Opin Psychiatry 2012; 25: 219-225.
8. Kooij JJ, Huss M, Asherson P, Akehurst R, Beusterien K, French A, Sasané R, Hodgkins P,. Distinguishing comorbidity and successful management of adult ADHD. J Atten Disord 2012; 16 (5 Suppl.): 3S-19S.
9. Turnquist K, Frances R, Rosenfeld W, Mobarak A,. Pemoline in attention deficit disorder and alcoholism: a case study. Am J Psychiatry 1983; 140: 622-624.
10. Weiss RD, Pope HG Jr, Mirin SM,. Treatment of chronic cocaine abuse and attention deficit disorder, residual type, with magnesium pemoline. Drug Alcohol Depend 1985; 15: 69-72.
11. Cocores JA, Davies RK, Mueller PS, Gold MS,. Cocaine abuse and adult attention deficit disorder. J Clin Psychiatry 1987; 48: 376-377.
12. Cavanagh R, Clifford JS, Gregory WL,. The use of bromocriptine for the treatment of attention deficit disorder in two chemically dependent patients. J Psychoactive Drugs 1989; 21: 217-220.
13. Levin FR, Evans SM, McDowell DM, Kleber HD,. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998; 59: 300-305.
14. Castaneda R, Sussman N, Levy R, Trujillo M,. A treatment algorithm for attention deficit hyperactivity disorder in cocaine-dependent adults: a one-year private practice study with long-acting stimulants, fluoxetine, and bupropion. Subst Abus 1999; 20: 59-71.
15. Upadhyaya HP, Brady KT, Sethuraman G, Sonne SC, Malcolm R,. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol 2001; 21: 116-118.
16. Somoza EC, Winhusen TM, Bridge TP, Rotrosen JP, Vanderburg DG, Harrer JM, Mezinskis JP, Montgomery MA, Ciraulo DA, Wulsin LR, Barrett JA,. An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder. J Addict Dis 2004; 23: 77-92.
17. Levin FR, Mariani JJ, Secora A, Brooks D, Cheng WY, Bisaga A, Nunes E, Aharonovich E, Raby W, Hennessy G,. Atomoxetine treatment for cocaine abuse and adult attention-deficit hyperactivity disorder (ADHD): a preliminary open trial. J Dual Diagn 2009; 5: 41-56.
18. Adler LA, Guida F, Irons S, Shaw DM,. Open label pilot study of atomoxetine in adults with ADHD and substance use disorder. J Dual Diagn 2010; 6: 196-207.
19. Wilens TE, Prince JB, Waxmonsky J, Doyle R, Spencer T, Martelon MK, Evans M,. An open trial of sustained-release bupropion for attention-deficit/ hyperactivity disorder (ADHD) in adults with ADHD plus substance use diorders. J ADHD Relat Disord 2010; 1: 25-35.
20. McRae-Clark AL, Brady KT, Hartwell KJ, White K, Carter RE,. Methylphenidate transdermal system in adults with past stimulant misuse: an open-label trial. J Atten Disord 2011; 15: 539-544.
21. Levin FR, Evans SM, McDowell DM, Brooks DJ, Nunes E,. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis 2002; 21: 1-16.
22. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, Edwards A, Donlin J, Pihlgren E,. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10: 286-294.
23. Carpentier PJ, de Jong CA, Dijkstra BA, Verbrugge CA, Krabbe PF,. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction 2005; 100: 1868-1874.
24. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV,. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006; 81: 137-148.
25. Levin FR, Evans SM, Brooks DJ, Garawi F,. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007; 87: 20-29.
26. Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, Renard D, Brady KT, Trzepacz PT, Schuh LM, Ahrbecker LM, Levine LR,. Atomoxetine ADHD/SUD Study Group. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008; 96: 145-154.
27. Konstenius M, Jayaram-Lindstrom N, Beck O, Franck J,. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 2010; 108: 130-133.
28. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT,. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict 2010; 19: 481-489.
29. Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD, Leimberger JD, Lewis DF, Dorer EM,. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71: 1680-1688.
30. Kollins SH, Youcha S, Lasser R, Thase ME,. Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder. Innov Clin Neurosci 2011; 8: 28-32.
31. Kollins SH, English JS, Itchon-Ramos N, Chrisman AK, Dew R, O'Brien B, McClernon FJ,. A pilot study of Lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults With ADHD. J Atten Disord 2012. in press. doi: 10.1177/1087054712440320.
32. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV,. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152: 1652-1658.
33. Kollins SH, McClernon FJ, Fuemmeler BF,. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry 2005; 62: 1142-1147.
34. DuPaul G, Power T, Anastopoulos A, Reid R,. ADHD Rating Scales-IV: Checklists, Norms and Clinical Interpretation. New York: Guilford Press, 1998.
35. Murphy K, Barkley RA,. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord 1996; 1: 147-161.
36. Collins SL, Levin FR, Foltin RW, Kleber HD, Evans SM,. Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend 2006; 82: 158-167.
37. Winhusen T, Somoza E, Singal BM, Harrer J, Apparaju S, Mezinskis J, Desai P, Elkashef A, Chiang CN, Horn P,. Methylphenidate and cocaine: a placebo-controlled drug interaction study. Pharmacol Biochem Behav 2006; 85: 29-38.
38. Stoops WW, Blackburn JW, Hudson DA, Hays LR, Rush CR,. Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance. Drug Alcohol Depend 2008; 92: 282-285.
39. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE,. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002; 67: 149-156.
40. Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ,. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 2008; 95: 140-146.
41. Parasrampuria DA, Schoedel KA, Schuller R, Silber SA, Ciccone PE, Gu J, Sellers EM,. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol 2007; 27: 459-467.
42. Parasrampuria DA, Schoedel KA, Schuller R, Gu J, Ciccone P, Silber SA, Sellers EM,. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J Clin Pharmacol 2007; 47: 1476-1488.
43. Jasinski DR, Krishnan S,. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009; 23: 419-427.
44. Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S,. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009; 23: 733-744.
45. Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, Casas M,. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 2011; 25: 157-169.
46. Caisley H, Müller U,. Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: a systematic review. Eur Psychiatry 2012; 27: 343-349.
47. Covey LS, Hu MC, Weissman J, Croghan I, Adler L, Winhusen T,. Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate. Nicotine Tob Res 2011; 13: 1003-1008.
48. Flory K, Lynam DR,. The relation between attention deficit hyperactivity disorder and substance abuse: what role does conduct disorder play? Clin Child Fam Psychol Rev 2003; 6: 1-16.
49. Charach A, Yeung E, Climans T, Lillie E,. Childhood attention-deficit/ hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry 2011; 50: 9-21.
50. Serra-Pinheiro MA, Coutinho ES, Souza IS, Pinna C, Fortes D, Araujo C, Szobot CM, Rohde LA, Mattos P,. Is ADHD a risk factor independent of conduct disorder for illicit substance use? A meta-analysis and metaregression investigation. J Atten Disord 2012. in press. doi: 10.1177/1087054711435362.
51. Schubiner H, Tzelepis A, Milberger S, Lockhart N, Kruger M, Kelley BJ, Schoener EP,. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000; 61: 244-251.
52. Lynskey MT, Hall W,. Attention deficit hyperactivity disorder and substance use disorders: is there a causal link? Addiction 2001; 96: 815-822.
53. Elkins IJ, McGue M, Iacono WG,. Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. Arch Gen Psychiatry 2007; 64: 1145-1152.
54. Fergusson DM, Horwood LJ, Ridder EM,. Conduct and attentional problems in childhood and adolescence and later substance use, abuse and dependence: results of a 25-year longitudinal study. Drug Alcohol Depend 2007; 88 (Suppl. 1): S14-26.
55. Wilens TE, Faraone SV, Biederman J, Gunawardene S,. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111: 179-185.
56. Barkley RA, Fischer M, Smallish L, Fletcher K,. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 2003; 111: 97-109.
57. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV,. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008; 165: 597-603.
58. Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, Castellanos FX,. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008; 165: 604-609.
59. Barkley RA, Fischer M, Smallish L, Fletcher K,. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry 2004; 45: 195-211.
60. Sinzig J, Döpfner M, Lehmkuhl G, German Methylphenidate Study Group. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007; 17: 421-432.
61. Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM, Pollack S,. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997; 54: 1073-1080.
62. Levin FR, Evans SM, Kleber HD,. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend 1998; 52: 15-25.
63. Pérez de los Cobos J, Siñol N, Puerta C, Cantillano V, Lõpez Zurita C, Trujols J,. Features and prevalence of patients with probable adult attention deficit hyperactivity disorder who request treatment for cocaine use disorders. Psychiatry Res 2011; 185: 205-210.
64. Delavenne H, Ballon N, Charles-Nicolas A, Garcia FD, Thibaut F, Lacoste J,. Attention deficit hyperactivity disorder is associated with a more severe pattern of cocaine consumption in cocaine users from French West Indies. J Addict Med 2011; 5: 284-288.
65. Levin FR, Evans SM, Vosburg SK, Horton T, Brooks D, Ng J,. Impact of attention-deficit hyperactivity disorder and other psychopathology on treatment retention among cocaine abusers in a therapeutic community. Addict Behav 2004; 29: 1875-1882.
66. Humfleet GL, Prochaska JJ, Mengis M, Cullen J, Munoz R, Reus V, Hall SM,. Preliminary evidence of the association between the history of childhood attention-deficit/hyperactivity disorder and smoking treatment failure. Nicotine Tob Res 2005; 7: 453-460.
67. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T,. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis 1997; 185: 475-482.
68. Biederman J, Wilens TE, Mick E, Faraone SV, Spencer T,. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 1998; 44: 269-273.
69. Field M, Cox WM,. Attentional bias in addictive behaviors: a review of its development, causes, and consequences. Drug Alcohol Depend 2008; 97: 1-20.
70. Crews FT, Boettiger CA,. Impulsivity, frontal lobes and risk for addiction. Pharmacol Biochem Behav 2009; 93: 237-247.
71. Seidman LJ,. Neuropsychological functioning in people with ADHD across the lifespan. Clin Psychol Rev 2006; 26: 466-485.
72. Vergara-Moragues E, González-Saiz F, Lozano Rojas O, Bilbao Acedos I, Fernández Calderõn F, Betanzos Espinosa P, Verdejo García A, Pérez García M,. Diagnosing adult attention deficit/hyperactivity disorder in patients with cocaine dependence: discriminant validity of Barkley executive dysfunction symptoms. Eur Addict Res 2011; 17: 279-284.
73. Verdejo-Garcia A, Bechara A,. A somatic marker theory of addiction. Neuropharmacology 2009; 56 (Suppl. 1): 48-62.
74. Wilens TE, Adamson J, Sgambati S, Whitley J, Santry A, Monuteaux MC, Biederman J,. Do individuals with ADHD self-medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD. Am J Addict 2007; 16 (Suppl. 1): 14-21.
75. Gray KM, Upadhyaya HP,. Tobacco smoking in individuals with attention-deficit hyperactivity disorder: epidemiology and pharmacological approaches to cessation. CNS Drugs 2009; 23: 661-668.
76. McClernon FJ, Kollins SH, Lutz AM, Fitzgerald DP, Murray DW, Redman C, Rose JE,. Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: results of a preliminary study. Psychopharmacology (Berl) 2008; 197: 95-105.
77. Conners CK, Levin ED, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J,. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull 1996; 32: 67-73.
78. Gehricke JG, Whalen CK, Jamner LD, Wigal TL, Steinhoff K,. The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: a preliminary examination. Nicotine Tob Res 2006; 8: 37-47.
79. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW,. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 2011; 69: e145-157.
80. Volkow ND, Fowler JS, Wang GJ, Swanson JM,. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004; 9: 557-569.
81. Hyman SE, Malenka RC, Nestler EJ,. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006; 29: 565-598.
82. Castells X, Casas M, Vidal X, Bosch R, Roncero C, Ramos-Quiroga JA, Capellà D,. Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomized controlled clinical trials. Addiction 2007; 102: 1871-1887.
83. Hester R, Lee N, Pennay A, Nielsen S, Ferris J,. The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence. Exp Clin Psychopharmacol 2010; 18: 489-497.
84. Kalechstein AD, De La Garza R 2nd, Newton TF,. Modafinil administration improves working memory in methamphetamine-dependent individuals who demonstrate baseline impairment. Am J Addict 2010; 19: 340-344.
85. Hurt RD, Ebbert JO, Croghan IT, Schroeder DR, Sood A, Hays JT,. Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial. J Negat Results Biomed 2011; 10: 1. doi: 10.1186/1477-5751-10-1.
86. Ray R, Rukstalis M, Jepson C, Strasser A, Patterson F, Lynch K, Lerman C,. Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence. J Psychopharmacol 2009; 23: 168-176.
87. Silverstone PH, Dadashova R,. Atomoxetine treatment for nicotine withdrawal: a pilot double-blind, placebo-controlled, fixed-dose study in adult smokers. Ann Gen Psychiatry 2012; 11: 6. doi: 10.1186/1744-859X-11-6.
88. Tirado CF, Goldman M, Lynch K, Kampman KM, Obrien CP,. Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. Drug Alcohol Depend 2008; 94: 254-257.
89. Levin FR,. Diagnosing attention-deficit/hyperactivity disorder in patients with substance use disorders. J Clin Psychiatry 2007; 68 (Suppl. 11): 9-14.
90. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fourth edn. Washington, DC: American Psychiatric Association, 1994.
91. Wilens TE,. The nature of the relationship between attention-deficit/ hyperactivity disorder and substance use. J Clin Psychiatry 2007; 68 (Suppl. 11): 4-8.
92. Faraone SV, Biederman J, Spencer T, Mick E, Murray K, Petty C, Adamson JJ, Monuteaux MC,. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry 2006; 163: 1720-1729.
93. Faraone SV, Wilens TE, Petty C, Antshel K, Spencer T, Biederman J,. Substance use among ADHD adults: implications of late onset and subthreshold diagnoses. Am J Addict 2007; 16 (Suppl. 1): 24-32.
94. Rizkallah E, Legault L, Pampoulova T, Levesque S, Belanger M, Stavro K, Chiasson JP, Potvin S,. A case report of Concerta misuse in a patient with comorbid substance use disorder and attention deficit hyperactivity disorder. Am J Addict 2011; 20: 478-479.
95. McGough JJ, Smalley SL, McCracken JT, Yang M, Del'Homme M, Lynn DE, Loo S,. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 2005; 162: 1621-1627.
96. Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S, Schaffer A, Weiss M,. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry 2012; 24: 23-37.
97. Santosh PJ, Sattar S, Canagaratnam M,. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs 2011; 25: 737-763.